Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Advanced Laboratory Medicine, |
RCV000852701 | SCV000995415 | likely benign | Primary dilated cardiomyopathy | 2018-07-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002536193 | SCV001540421 | uncertain significance | Rienhoff syndrome | 2022-08-16 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs766164843, gnomAD 0.02%). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 691733). This variant has not been reported in the literature in individuals affected with TGFB3-related conditions. This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 295 of the TGFB3 protein (p.Gly295Arg). |
Ambry Genetics | RCV004029273 | SCV003711400 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2022-05-06 | criteria provided, single submitter | clinical testing | The c.883G>C (p.G295R) alteration is located in exon 5 (coding exon 5) of the TGFB3 gene. This alteration results from a G to C substitution at nucleotide position 883, causing the glycine (G) at amino acid position 295 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |